Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Rhea-AI Summary

Diffusion Pharmaceuticals (DFFN) reported financial results for Q1 2022, ending with $32.6 million in cash and equivalents, supporting operations through 2023. The Company completed dosing in the Altitude Trial, with topline data expected in June 2022. Additionally, enrollment in the TSC ILD-DLCO trial continues, targeting mid-2022 completion. General and administrative expenses rose to $2.1 million while R&D expenses decreased to $2.4 million. Notably, Diffusion regained compliance with Nasdaq listing requirements.

Positive

• Topline data from the Altitude Trial expected in June 2022.
• Strong cash position of $32.6 million to fund operations through 2023.
• Completion of dosing in the Altitude Trial and continued enrollment in ILD-DLCO trial.
• Expanded Scientific Advisory Board with prominent oncologists.

Negative

• General and administrative expenses increased to $2.1 million.
• Decline in cash reserves from $46.6 million in Q1 2021.

• Completed Dosing in Altitude Trial; Topline Data Expected in June 2022
• Blinded, Interim Data to be Presented at UHMS Annual Scientific Meeting in May 2022
• Ended Quarter with $32.6 Million in Cash, Cash Equivalents and Marketable Securities
  
• Regained Compliance with Nasdaq Bid Price Rule

CHARLOTTESVILLE, Va., May 12, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced financial results for the quarter ended March 31, 2022, and provided a business update.

Business Updates

• Completed Dosing in Altitude Trial: The Company announced the last participant in this study of its lead product candidate, trans sodium crocetinate (“TSC”), completed dosing in April 2022 and topline data are expected in June 2022. Two abstracts, based on blinded, aggregated (placebo and treatment), interim physiological data from a subset of study participants, will be presented by the clinical investigators at the Undersea and Hyperbaric Medical Society’s Annual Scientific Meeting in Reno, Nevada being held from May 22-26, 2022.
• Continued Enrollment in TSC ILD-DLCO Trial: Diffusion announced dosing of the first patients in December 2021 and enrollment continued during the first quarter of 2022. The Company currently anticipates completing dosing in the second half of 2022 and reporting topline results within two months of study completion.
• Expanded Scientific Advisory Board: In February 2022, the Company announced the addition of five prominent radiation and medical oncologists to its Scientific Advisory Board (“SAB”) to further support development of TSC, as an adjunctive treatment for hypoxic solid tumors.
• Maintained Solid Cash Position: As of March 31, 2022, Diffusion reported $32.6 million in cash, cash equivalents, and marketable securities, which is expected to fund the Company’s operating expenses and capital expenditure requirements through 2023.
• Regained Nasdaq Compliance: In May 2022, the Company announced that it had regained compliance with the Nasdaq Capital Market’s continued listing requirements, following the bid price of the Company’s common stock closing above $1.00 for 10 consecutive trading days.
  

“We believe 2022 has the potential to be a transformational year, as we anticipate the topline data readout from the Altitude Trial in June and the completion of patient dosing in our ILD-DLCO trial later this year,” commented Robert Cobuzzi, Jr., Ph.D., President and Chief Executive Officer of Diffusion. “With our strong cash position, experienced development team, and the appointment of our new and distinguished SAB members, we believe Diffusion is now effectively positioned to launch our Hypoxic Solid Tumor Program aimed at evaluating TSC as an adjunctive treatment for hypoxic solid tumors. Our team worked hard during the first quarter, evaluating various options in designing an appropriate clinical study protocol and amending our oncology investigational new drug application for TSC to support a start date for the first trial in the program in the second half of 2022. We look forward to providing updates on these development activities that we hope will drive both patient and shareholder value.”

Financial Results

• Research and development expenses in the first quarter of 2022 were $2.4 million, compared to $2.9 million in the prior year period. A significant portion of this decrease was attributable to the timing of clinical trials and drug manufacturing, offset by an increase in salaries, wages and stock-based compensation related to increased headcount.
  
  
• General and administrative expenses were $2.1 million during the first quarter of 2022 versus $1.7 million in the comparable quarter last year. The increase compared to the prior year period was mainly due to an increase in salaries, wages, and stock-based compensation related to increased headcount, as well as an increase in outside professional fees to support business activities during the quarter.
  
  
• As of March 31, 2022, Diffusion had cash, cash equivalents, and marketable securities of $32.6 million, compared to $46.6 million as of March 31, 2021.
  

About Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most. Diffusion’s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions, including hypoxic solid tumors. For more information, please visit us at www.diffusionpharma.com.

Forward-Looking Statements
This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company’s anticipated cash runway, anticipated timelines for the initiation, completion, and announcement of data from the Company’s Oxygenation Trials and hypoxic solid tumor program, the relevance and significance of any such data, and the potential therapeutic value of TSC. The Company may, in some cases, use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, the Company’s actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risk and uncertainties include, among other things, those related to: the Company’s ability to design, initiate, enroll, execute, and complete its planned studies evaluating TSC; the likelihood and timing of regulatory approval of TSC, if any, for the treatment of solid tumors complicated by hypoxia or any other indication, or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration or other regulatory bodies; the impact of supply chain and other supplier issues on the Company’s clinical development program and associated timelines; the Company’s ability to protect and expand its intellectual property portfolio; general economic, political, business, industry, and market conditions, including the ongoing COVID-19 pandemic, inflationary pressures, and geopolitical conficts; and the other factors discussed under the heading “Risk Factors” in the Company’s filings most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified) and, except as required by applicable law, rule, or regulation, the Company undertakes no obligation to update any such statements after the date hereof.

Contacts

Investors:  
Tiberend Strategic Advisors, Inc. 
Daniel Kontoh-Boateng
dboateng@tiberend.com

Media:  
Kate Barrette
RooneyPartners  
Kbarrette@rooneypartners.com

Diffusion Pharmaceuticals Inc.
Balance Sheets

	March 31, 2022			December 31, 2021
Assets
Current assets:
Cash and cash equivalents	$	9,872,330		$	37,313,558
Marketable securities		22,680,303			—
Prepaid expenses, deposits and other current assets		1,021,496			510,015
Total current assets		33,574,129			37,823,573
Other assets		—			15,578
Total assets	$	33,574,129		$	37,839,151
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	813,197		$	947,495
Accrued expenses and other current liabilities		2,142,633			1,980,189
Total current liabilities		2,955,830			2,927,684
Stockholders’ Equity:
Series C convertible preferred stock, $0.001 par value: 10,000 shares authorized; 10,000 and 0 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively		5,000
Common stock, $0.001 par value: 1,000,000,000 shares authorized; 2,038,392 and 2,038,185 shares issued and outstanding at March 31, 2021 and December 31, 2021, respectively		2,038			2,038
Additional paid-in capital		165,192,671			164,914,540
Accumulated other comprehensive loss		(49,658	)		—
Accumulated deficit		(134,531,752	)		(130,005,111	)
Total stockholders' equity		30,618,299			34,911,467
Total liabilities and stockholders' equity	$	33,574,129		$	37,839,151

Diffusion Pharmaceuticals Inc.
Statement of Operations

		Three Months ended March 31,
		2022				2021
Operating expenses:
Research and development		$	2,425,898			$	2,916,378
General and administrative			2,128,552				1,743,510
Depreciation			—				24,447
Loss from operations			4,554,450				4,684,335
Interest income			(27,809	)			(40,416	)
Net loss		$	(4,526,641	)		$	(4,643,919	)
Per share information:
Net loss per share of common stock, basic and diluted		$	(2.22	)		$	(2.81	)
Weighted average shares outstanding, basic and diluted			2,038,323				1,649,969
Comprehensive loss:
Net loss		$	(4,526,641	)		$	(4,643,919	)
Unrealized loss on marketable securities			(49,658	)			-
Comprehensive loss:		$	(4,576,299	)		$	(4,643,919	)

 

 

FAQ

What are the financial results for Diffusion Pharmaceuticals (DFFN) in Q1 2022?

For Q1 2022, Diffusion reported cash and equivalents of $32.6 million, R&D expenses of $2.4 million, and general administrative expenses of $2.1 million.

When will topline data from the Altitude Trial be available for DFFN?

Topline data from the Altitude Trial is expected to be released in June 2022.

What is the current cash position of Diffusion Pharmaceuticals (DFFN)?

As of March 31, 2022, Diffusion Pharmaceuticals reported a cash position of $32.6 million.

Has Diffusion Pharmaceuticals regained compliance with Nasdaq requirements?

Yes, Diffusion regained compliance with Nasdaq listing requirements in May 2022.